Ion channels are among the most technically demanding targets in modern drug discovery. This free eBook outlines how Sygnature Discovery addressed these challenges through custom-built assays, specialist electrophysiology platforms and one of the largest ion channel...
High-throughput, physiologically relevant ion channel characterization using RealDRGx™ sensory neurons Translational Relevance of iPSC-Derived Sensory Neurons To address the critical need for scalable and human-relevant models in pain research, we validated an...
Advancing Kv2.2 Drug Discovery Sygnature Discovery's ion channel screening platform provides reliable, high-quality data to support the search of novel starting points for Kv2.2 drug discovery. By integrating well-characterized cellular models with high-throughput...
Sygnature Discovery's TRPML drug discovery platform delivers comprehensive solutions for advancing TRPML1, TRPML2 and TRPML3 research. With advanced cell-based assay capabilities and a full suite of technologies, including fluorescence-based assays, solid-supported...
Introduction CLC-Ka and CLC-Kb are members of the CLC family of chloride channels and transporters, crucial for maintaining chloride ion homeostasis across cell membranes. CLC-Ka is predominantly found in the thin ascending limb of Henle’s loop, while CLC-Kb is...
GRIN variant screening using automated electrophysiology enables precise assessment of gain- and loss-of-function variants in the NMDA receptor GRIN gene family. Sygnature Discovery's high-throughput platform supports detailed functional analysis to accelerate NMDA...
TRPML1 screening using solid supported membrane electrophysiology (SSME) provides a robust, high-throughput platform for profiling channel modulators. Sygnature Discovery applies this approach to accelerate early-stage discovery of TRPML1-tagreting therapeutic. ...
CLC-1 and CLC-2 screening using automated electrophysiology enables high-throughput analysis of chloride channel function. Sygnature Discovery applies this advanced platform to support detailed profiling and lead optimization in ion channel drug discovery....
GABAA receptor screening enables detailed evaluation of subtype-selective modulation using automated electrophysiology. Sygnature Discovery supports CNS drug discovery with robust assay platforms for characterizing GABAA receptor activity and pharmacology....
TRPML1 screening using automated electrophysiology provides a robust and efficient platform for ion channel drug discovery. Sygnature Discovery leverages this approach to support compound profiling, mechanism of action studies and lead optimization. Introduction...
TMEM175 screening using a multi-platform approach - including electrophysiology and fluorescence-based assays - enables comprehensive profiling and characterization. Sygnature Discovery supports ion channel drug discovery through flexible, high-quality TMEM175 assay...
BK channel screening allows investigation of the functional and pharmacological impact of β-subunit expression using electrophysiology. Sygnature Discovery provides detailed profiling to support BK channel-focussed drug discovery and lead optimization. Introduction BK...